Lymphodepleting chemotherapy Clinical Trials
9 recruitingDrug
Phase 19Phase 27
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
Non-small Cell Lung CancerAdvanced/Metastatic
Beijing Biotech60 enrolled1 locationNCT07641023
Recruiting
Phase 1
Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma
Phase 1Clear Cell CarcinomaGrowth Factor
M.D. Anderson Cancer Center30 enrolled1 locationNCT07072234
Recruiting
Phase 1
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Multiple Myeloma
Washington University School of Medicine25 enrolled1 locationNCT06185751
Recruiting
Phase 1Phase 2
PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors
Advanced or Metastatic Solid Tumors
Beijing Biotech60 enrolled1 locationNCT07510828
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
HER2-positive Breast CancerTriple Negative Breast Cancer(TNBC)Breast Cancer (Locally Advanced or Metastatic)
Beijing Biotech60 enrolled1 locationNCT07486089
Recruiting
Phase 1Phase 2
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Primary Peritoneal CarcinomaFallopian Tube CarcinomaEpithelial Ovarian Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07480954
Recruiting
Phase 1Phase 2
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
SCLC,Extensive StageSmall Cell Lung Cancer ( SCLC )Relapsed/Refractory SCLC
Beijing Biotech60 enrolled1 locationNCT07480213
Recruiting
Phase 1Phase 2
Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Non-small Cell Lung CancerAdvanced/Metastatic NSCLC
Beijing Biotech48 enrolled1 locationNCT07467863
Recruiting
Phase 1Phase 2
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
IgG4-related Disease
Acepodia Biotech, Inc.30 enrolled3 locationsNCT07061938